Vaccination against influenza in patients with systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Litinsky, Ira ^a   Balbir, Alexandra ^b   Zisman, Devy ^c   Mandelboim, Michal ^d   Mendelson, Ella ^d   Feld, Joy ^c   Braun, Yolanda ^b   Anouk, Marina ^a   Kaufman, Ilana ^a   Paran, Daphna ^a   Caspi, Dan ^a   Elkayam, Ori ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Rambam Health Care Campus Background ^*  (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Influenza; Systemic sclerosis; Vaccine

Indexed keywords

C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; JOINT SWELLING; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; ULCER; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ISRAEL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84863756343     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Tamby MC, Guillevin L, Mouthon L: New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003; 2: 152-157.
2. Steen VD, Medsger TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
3. Hesselstrand R, Scheja A, Akesson A: Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682- 686.
4. Hachulla E, Clerson P, Launay D et al.: Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007; 34: 2423-2430.
5. Vonk MC, Marjanovic Z, Van Dden Hoogen FH et al.: Long-term follow-up results after autologous haemapoetic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008; 67: 98-104.
6. PREVENTION OF INFLUENZA: Recommendation of the Advisory Committee on Immunization Practices (ACIP). National Center for Immunization and Respiratory Diseases (proposed). CDC July 28, 2006/55(RR10):1-2
7. Fomin I, Caspi D, Levy V et al.: Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF blockers. Ann Rheum Dis 2006; 65: 191-194.
8. Chalmers A, Scheifele D, Patterson D, Williams D, Weber J, Shuckett R: Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Reumatol 1994; 21: 1203-1206.
9. Elkayam O, Bashkin A, Mandelboim M et al.: The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442-447.
10. Setti M, Fnoglio D, Ansaldi F et al.: Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009; 27: 3367-3372.
11. Leroy EC, Medsger TA JR: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576.
12. COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMC): Note for guidance on harmonization of requirements for influenza vaccines. CPMB/BWP/214/96, 1996, Circular No 96-0666, pp 1-22.
13. COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMC): Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines, 2001, CPMP/EPW/1045/01.
14. Palmer DF, Coleman MT, Dowdle WR, Schild DC: Advanced laboratory techniques for influenza diagnosis, Public Health service. US Department of Health, Education and Welfare. Atlanta: Centers for Disease Control, 1975.
15. Mercado U, Acosta H, Diaz-Molina R: Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis. J Rheumatol 2009; 36: 1549-1550.
16. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y: Vaccines and autoimmunity. Nat Rev Rheumatol 2009; 5: 648-652.
17. Drago F, Rampini P, Lugani C, Rebora A: Generalized morphoea after antitetanus vaccination. Clin Exp Dermatol 1998; 23: 142.
18. Schmutz JL, Posth M, Granel F, Trechot P, Barbaud A: Localized scleroderma after hepatitis B vaccination. Presse Med 2000; 29: 1046.
19. Torrelo A, Suárez J, Colmenero I, Azorín D, Perera A, Zambrano A: Deep morphea after vaccination in two young children. Pediatr Dermatol 2006; 23: 484-487.
20. Chalmers A, Scheifele D, Patterson C et al.: Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 21: 1203-1206.
21. Launay O, Guillevin L, Mouthon L: Immunizations in adult patients with systemic sclerosis. Ann NY Acad Sci 2009; 1173: 610-618.